Effect of Perioperative Neurostimulation in Patients Undergoing Whipple Operation (Pancreaticoduodenectomy) on Acute Postsurgical Inflammatory Response [ENSWAPI-trial]

Pancreaticoduodenectomy Clinical Trial

Official title:

Effect of Perioperative Neurostimulation in Patients Undergoing Whipple Operation (Pancreaticoduodenectomy) on Acute Postsurgical Inflammatory Response [ENSWAPI-trial]

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05743530
• Other study ID #: ENSWAPI
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 15, 2023
• Est. completion date: September 2025

Study information

• Verified date: February 2023
• Source: Medical University of Graz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to test whether electrical stimulation of the vagus nerve via a device placed on the top of the external ear can reduce the postoperative inflammatory reaction after Whipple's surgery (pancreatoduodenectomy).

Description:

Following surgery, inflammation normally is a balanced event, which is resolved in a timely manner. But, disrupted immune regulation can result in continuous proinflammatory cytokine activity and excessive or chronic inflammation. In the case of major surgical interventions, the inflammatory reaction is not limited to the area of surgery, but takes place systemically via various mediators. The cytokines IL-1, TNF-α and IL-6, which are formed by the leukocytes, are responsible for associated clinical symptoms like fever, fatigue and general feeling of illness. By crossing the blood-brain barrier, IL-6 initiates the synthesis of prostaglandin E2 (PGE2), and IL-6 also facilitates energy mobilizations in muscle and fat tissue. The release of acute phase proteins from the hepatocytes of the liver is also effected via cytokines. These include fibrinogen and C-reactive protein (CRP), which are involved in the removal of entered microorganisms with opsonization and complement fixation. However, if too many of these cytokines are present or if they are released for prolonged periods, this can lead to an intensified inflammatory process, which is also called systemic inflammatory response syndrome (SIRS) if certain criteria are met. These criteria include systemic activation of the coagulation cascade, disseminated intravascular coagulation (DIC), Acute Respiratory Distress Syndrome (ARDS) and Multi Organ Failure (MOF). In the worst case, this ends with the patient's death. In order to avoid destruction by one's own immune system, pro-inflammatory mediators are only released for a short time. In addition, the organism forms anti-inflammatory mediators such as Transforming Growth Factor Beta (TGF-ß) and IL-10, which is formed by the TH2 subtype of CD4 positive T lymphocytes. They counteract the inflammatory process by downregulating the immune response and thus limiting the destruction of the tissue.

A well-functioning immune system is essential for surgery. The interaction of inflammation and anti-inflammation ensures the destruction of the destroyed tissue and prevents penetrating microorganisms from developing an infection. An excessive pro-inflammatory reaction can lead to a SIRS, a possibly reactive strong post-operative immunosuppression facilitates the penetration of pathological microorganisms and thus predisposes to infection. Unfortunately, postoperative infectious and non-infectious postoperative complications do occur in spite of preventive treatment with antibiotics immediately before or during surgical treatment and have so far been treated upon their occurrence during the postoperative recovery period.

An analysis on postoperative morbidity associated with inflammation in pancreatic surgery (own database (n=275)) showed the development of postoperative sepsis in 4% (n=11), which had an abdominal focus in 2.9% (n=8) and other localizations in 1.1% (n=3). Postoperative pneumonia has been reported to occur after pancreatic resection in 1-6% of cases and has been associated with both pancreatic fistula and delayed gastric emptying (DGE), and has been reported to be associated with a very high 90-day-mortality [6]. IL-6 is a major mediator of inflammation, and it is important to elucidate that IL-6 is part of a complex, interdepending network of cytokines released in inflammatory conditions [7]. In healthy adults, IL-6 concentrations in the plasma are <10 pg/ml [8]. IL-6 is particularly important in chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, Castlemann's disease, haematopoietic diseases and after physical stress such as surgery or chemotherapy. Increased levels of serum and/or tumor IL-6 are also seen in a number of malignant conditions, both haematopoietic malignancies and solid tumors including breast, cervical, esophageal, head-and-neck, ovarian, prostate, colorectal, pancreatic, hepatocellular, gall bladder, non-small-cell lung cancer and multiple myeloma, reflecting the immunological involvement in cancer. Several studies have shown IL-6 to be a prognostic indicator of survival as well as predictive in response to therapy in many types of cancer [9, 10]. A high IL-6 level is generally associated with a poorer outcome and with more severe symptoms in regards to cancer as well as the development of anti-cancer drug resistance [11, 12].

Endogenous mechanisms that prevent or neutralize excessive proinflammatory reactions could lead to novel therapeutic options.

Transcutaneous electrical neurostimulation (TENS) is a non-invasive physiotherapeutic resource for pain management, but evidence on the effectiveness of this device at reducing proinflammatory cytokines in the blood is unclear.

TENS is a strategy that allows for interaction with the peripheral vascular system or with the autonomic nervous system.

The vagus nerve is the main nerve of the parasympathetic division of the autonomic nervous system. The vagus nerve regulates metabolic homeostasis by controlling heart rate, gastrointestinal motility and secretion, pancreatic endocrine and exocrine secretion, hepatic glucose production, and many other visceral functions over the brainstem. In addition, afferent and efferent branches of the vagus nerve are part of a neural reflex mechanism (the inflammatory reflex) that controls innate immune responses and inflammation during pathogen invasion and tissue injury [1, 2, 3]. Innate immune responses are activated by pathogen-associated and danger-associated molecular patterns. Activation of downstream signaling cascades results in increased production and release of tumor necrosis factor (TNF), IL-6 and other proinflammatory cytokines. These are implicated in extracellular pathogen clearance, vasodilatation, neutrophil recruitment, increased vascular permeability and induction of acute-phase proteins, such as C-reactive protein (CRP), and coagulation molecules. Proinflammatory progression is balanced by the release of IL-10, TGF-ß and other anti-inflammatory molecules.

Communication between the immune system and the brain is vital for controlling inflammation by the inflammatory reflex (the afferent vagus nerve signalling, which is activated by cytokines or pathogen-derived products, is functionally associated with efferent vagus nerve-mediated regulation of proinflammatory cytokine production and inflammation) [2, 3]. The inflammatory reflex is a physiological mechanism through which the nervous system maintains immunologic homeostasis by modulating innate and adaptive immunity. The absence of this inflammatory reflex leads to excessive immune responses and cytokine toxicity. It could be shown that the severity of collagen-induced arthritis can be reduced by neurostimulation of the cholinergic anti-inflammatory pathway, supporting the rationale for testing this approach in human inflammatory disorders [4]. Koopman et al. have shown that the vagus nerve stimulation (up to four times daily) for the reduction of the frequency of epileptic seizures had an effect also on the activity of rheumatoid arthritis. The vagus nerve stimulation significantly inhibited the TNF production for up to 84 days [5]. These results establish that vagus nerve stimulation modulates TNF production and reduces inflammation in humans. Gürgen et al. found that distinctive decreases of pro-inflammatory cytokines observed in the dermis in the vagus nerve stimulation group suggest that TENS shortened the healing process by inhibiting the inflammation phase in an animal model on wound healing in terms of the expression levels of pro-inflammatory cytokines [13]. We intend to investigate the effect of perioperative vagus nerve stimulation by application of the Neurostimulator V by Ducest in patients undergoing Whipple operation (pancreaticoduodenectomy).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients (male/female) scheduled for Whipple procedure (pancreaticoduodenectomy)

• Ability of subject to understand character and individual consequences of the clinical trial

• Written informed consent must be available before enrolment in the trial

Exclusion Criteria:

• Patients < 18 and > 90 years of age

• Simultaneous participation in other clinical trials

• Pregnancy

• Current infection

• Hemophilia

• Psoriasis vulgaris

• Pacemaker, implanted cardioverter defibrillator, cardiac resynchronization therapy

Related Conditions & MeSH terms

• Pancreaticoduodenectomy

Intervention

Device:
• TENS - transcutaneous electrical nerve stimulation
Pre-operative day 1 till postoperative day 14.

Other:
• Placebo
Pre-operative day 1 till postoperative day 14.

Locations

Country	Name	City	State
Austria	Allgemein,- Viszeral,- Transplantationschirurgie LKH Graz	Graz	Steiermark

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

References & Publications (15)

Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care. 2002 Aug;6(4):298-305. doi: 10.1186/cc1514. Epub 2002 May 24. — View Citation

Gurgen SG, Sayin O, Cetin F, Tuc Yucel A. Transcutaneous electrical nerve stimulation (TENS) accelerates cutaneous wound healing and inhibits pro-inflammatory cytokines. Inflammation. 2014 Jun;37(3):775-84. doi: 10.1007/s10753-013-9796-7. — View Citation

Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. doi: 10.1038/nrclinonc.2018.8. Epub 2018 Feb 6. — View Citation

Koca YS, Bulbul M, Barut I. The Diagnostic Roles of Cytokines in Hepatobiliary Cancers. Biomed Res Int. 2017;2017:2979307. doi: 10.1155/2017/2979307. Epub 2017 Dec 19. — View Citation

Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R, Tracey KJ, Tak PP. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8284-9. doi: 10.1073/pnas.1605635113. Epub 2016 Jul 5. — View Citation

Levine YA, Koopman FA, Faltys M, Caravaca A, Bendele A, Zitnik R, Vervoordeldonk MJ, Tak PP. Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis. PLoS One. 2014 Aug 11;9(8):e104530. doi: 10.1371/journal.pone.0104530. eCollection 2014. — View Citation

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6. doi: 10.1097/01.CCM.0000050454.01978.3B. — View Citation

Nagle RT, Leiby BE, Lavu H, Rosato EL, Yeo CJ, Winter JM. Pneumonia is associated with a high risk of mortality after pancreaticoduodenectomy. Surgery. 2017 Apr;161(4):959-967. doi: 10.1016/j.surg.2016.09.028. Epub 2016 Nov 8. — View Citation

Patel SA, Gooderham NJ. IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b. Mol Cancer Res. 2015 Nov;13(11):1502-8. doi: 10.1158/1541-7786.MCR-15-0147. Epub 2015 Jul 16. — View Citation

Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex--linking immunity and metabolism. Nat Rev Endocrinol. 2012 Dec;8(12):743-54. doi: 10.1038/nrendo.2012.189. — View Citation

Song M, Kellum JA. Interleukin-6. Crit Care Med. 2005 Dec;33(12 Suppl):S463-5. doi: 10.1097/01.ccm.0000186784.62662.a1. No abstract available. — View Citation

Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009 Jun;9(6):418-28. doi: 10.1038/nri2566. — View Citation

Tracey KJ. The inflammatory reflex. Nature. 2002 Dec 19-26;420(6917):853-9. doi: 10.1038/nature01321. — View Citation

Trefz P, Rosner L, Hein D, Schubert JK, Miekisch W. Evaluation of needle trap micro-extraction and automatic alveolar sampling for point-of-care breath analysis. Anal Bioanal Chem. 2013 Apr;405(10):3105-15. doi: 10.1007/s00216-013-6781-9. Epub 2013 Feb 7. Erratum In: Anal Bioanal Chem. 2013 Jun;405(16):5617. — View Citation

Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018 Jul 3;9(51):29820-29841. doi: 10.18632/oncotarget.25661. eCollection 2018 Jul 3. — View Citation

* Note: There are 15 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IL-6 levels change	IL-6 levels change between baseline and postoperative day 1. Baseline is defines as the serum concentration IL-6 at 24h prior to surgery	Baseline and postoperative day 1
Secondary	Post surgical inflammatory response (IL-1)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IL-6)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IL-8)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IL-13)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IL-10)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IL-18)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (TLF-alpha)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IFN-gamma)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (IL-1-beta)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (Serum Zonulin)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (LPS)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (Serum Ketone)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (HBA1c)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (NH3)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	Post surgical inflammatory response (GLP-1)	measurement of several cytocine levels over time	before surgery, day 1 and day 4 after surgery
Secondary	AST	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	AP	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	GGT	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	ALT	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	LDH	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	CK	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	Bilirubin	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	CRP	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	Procalcitronin	routine clinical parameters	Before surgery; daily between day 1 and day 7, on day 14 and day 90 after surgery
Secondary	VOCs		1x preoperative and on postoperative day 4
Secondary	Microbiome analysis	S-16 based microbiomanalysis (oral swap)	1x preoperative and on postoperative day 4
Secondary	Microbiome analysis	Pancreatic fluid	1x interoperatively